Don’t Count on Biogen Stock Gains — Alzheimer’s Drug Has Baggage
In this episode of The Bull & The Bear, I tell you if Biogen stock (Nasdaq: BIIB) is a buy after its recent Alzheimer’s drug breakthrough.
Posted by Matthew Clark | Jun 10, 2021 | Investing, Podcast
In this episode of The Bull & The Bear, I tell you if Biogen stock (Nasdaq: BIIB) is a buy after its recent Alzheimer’s drug breakthrough.
Posted by Matthew Clark | Jun 6, 2021 | Investing
Money & Markets Week Ahead for June 6, 2021: GameStop’s earnings should tell us if this “meme” stock’s recent surge is warranted.
Posted by Matthew Clark | Jun 5, 2021 | Investing, Podcast
In this week’s episode of The Bull & The Bear, Adam, Charles and I look at how to approach investing during the “shortage economy” of 2021.
Posted by Matthew Clark | Jun 4, 2021 | Investing
In this week’s Marijuana Market Update, I dig through some of the bigger cannabis mergers and acquisitions of 2021.
Posted by Matthew Clark | Jun 3, 2021 | Investing, Podcast
Social media activity has pushed “meme” stocks like AMC and GME to incredible heights. But there’s a problem with following the crowd…
In his free newsletter, What My System Says Today, Adam O’Dell uses his Green Zone Power Rating system to keep you in the know and focused on the market’s best (and worst) opportunities. It’s a data-driven approach underpinned by Wall Street-caliber tools you can only get here at Money & Markets. Sign up for FREE access to our daily emails now!
Enter your username and password below